Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial

NCT04722978 is registered in ClinicalTrials.gov with Sun Yat-Sen University Cancer Center as lead sponsor.

NCT NCT04722978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04722978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial
Lead sponsor
Sun Yat-Sen University Cancer Center
Phase
Phase 3
Overall status
Recruiting
Start date
April 20, 2021
Completion date
July 31, 2026
Enrollment
228 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer